drugset / Trial / NCT00954590

A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease

NCT00954590

Phase 3 Terminated 89 enrolled Medivation, Inc. Pfizer · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine if Dimebon is safe and effective in patients with moderate to severe Alzheimer's disease.

Timeline

Start
2009-10
Primary completion
2010-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Latrepirdine Small molecule 20 mg Oral

Indications

No indication recorded.